Atlas Trials

Study of Safety,Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia

Clinical trial NCT02981745 · UNKNOWN

Trial details

NCT number
NCT02981745
Sponsor
Centaurus Biopharma Co., Ltd.
Status
UNKNOWN
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Relapsed or Refractory B Cell Non-Hodgkin LymphomaChronic Lymphocytic LeukemiaWaldenstrom's MacroglobulinemiaMantle Zone Lymphoma Refractory/RecurrentFollicle Centre Lymphoma DiffuseDiffuse Large B Cell Lymphoma
Start date
2017-04-01
Primary completion
2018-09-01
Enrollment
200

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.